Target intelligence / Profile preview

Forkhead box protein D2 (FOXD2)

Target
FOXD2
Molecular classification
Transcription factor, Forkhead box family
01

Overview

Forkhead box protein D2 (FOXD2) is a member of the evolutionarily conserved forkhead family of transcription factors, defined by a forkhead DNA-binding domain. FOXD2 modulates developmental processes and intracellular signaling, especially in neural and mesoderm tissues, and plays a critical role in T cell activation by regulating components of the cAMP-dependent protein kinase pathway. In human colorectal cancer, FOXD2 functions as a chromatin-tuning factor; it remodels enhancer–promoter interactions and recruits MLL4/KMT2D, thereby inducing H3K4 monomethylation that triggers apoptosis through p53-responsive genes and suppresses tumor growth. FOXD2 dysregulation is linked to various cancers and is proposed as a tumor suppressor, while non-coding RNAs transcribed from the FOXD2 locus (e.g., FOXD2-AS1) act as oncogenic drivers and prognostic biomarkers in multiple tumor types.

Other names
FKHL17FREAC9FREAC-9Forkhead-related protein FKHL17Forkhead-related transcription factor 9forkhead, drosophila, homolog-like 17forkhead-like 17forkhead-related activator 9
02

Mechanism of action

As a transcription factor, FOXD2 modulates enhancer/promoter interactions and recruits MLL4/KMT2D, leading to H3K4 monomethylation, chromatin opening, and activation of tumor suppressor genes and apoptosis pathways, especially p53-responsive genes in colorectal cancer

03

Biological functions

Regulation of developmental patterningEpigenetic modulation (chromatin tuning)Modulation of intracellular signalingRegulation of T cell activationInduction of apoptosisCell cycle regulation
04

Disease associations

Cancer (colorectal cancer, prostate cancer, lymph node metastasis, various solid tumors)Tumor suppression (particularly in colorectal cancer via apoptosis and chromatin remodeling)Immunoregulation (T cell activation)
05

Biomarkers

FOXD2 expression in tumor tissue (especially colorectal cancer) is prognostic; low expression correlates with poor survivalFOXD2-antisense RNA (FOXD2‐AS1) overexpression is associated with adverse cancer outcomes and is a proposed biomarker for tumor progression

Beyond the preview

Go deeper on Forkhead box protein D2 (FOXD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forkhead box protein D2 (FOXD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call